Premium
The clinical efficacy of tolterodine extended‐release is maintained for 24 h in patients with overactive bladder
Author(s) -
Dmochowski Roger,
Kreder Karl,
MacDiarmid Scott,
Carlsson Martin,
Guan Zhonghong
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.06926.x
Subject(s) - tolterodine , medicine , overactive bladder , urination , urology , placebo , urinary incontinence , urinary system , alternative medicine , pathology
OBJECTIVE To assess the 24‐h efficacy of tolterodine extended‐release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI). PATIENTS AND METHODS We conducted a post hoc analysis of a 12‐week, placebo‐controlled trial of tolterodine‐ER in patients with frequency (≥8 voids/24 h) and UUI (≥5 episodes/week) for ≥ 6 months. Seven‐day bladder diaries were used to record diary endpoints; 24‐h diary data were stratified by 6‐h periods beginning at midnight. RESULTS Compared with placebo (508 patients), tolterodine‐ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval. CONCLUSIONS These results indicate that tolterodine‐ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.